Cargando…
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
BACKGROUND: Medulloblastoma is a leading cause of childhood cancer-related deaths. Current aggressive treatments frequently lead to cognitive and neurological disabilities in survivors. Novel targeted therapies are required to improve outcome in high-risk medulloblastoma patients and quality of life...
Autores principales: | Pajtler, Kristian W, Weingarten, Christina, Thor, Theresa, Künkele, Annette, Heukamp, Lukas C, Büttner, Reinhard, Suzuki, Takayoshi, Miyata, Naoki, Grotzer, Michael, Rieb, Anja, Sprüssel, Annika, Eggert, Angelika, Schramm, Alexander, Schulte, Johannes H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893444/ https://www.ncbi.nlm.nih.gov/pubmed/24252778 http://dx.doi.org/10.1186/2051-5960-1-19 |
Ejemplares similares
-
RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017) -
Identification
of the KDM2/7 Histone Lysine Demethylase
Subfamily Inhibitor and its Antiproliferative Activity
por: Suzuki, Takayoshi, et al.
Publicado: (2013) -
The Histone Demethylase KDM5 Is Essential for Larval Growth in Drosophila
por: Drelon, Coralie, et al.
Publicado: (2018) -
The nuclear bodies formed by histone demethylase KDM7A
por: Ming, Hui, et al.
Publicado: (2020) -
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)